Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:MRK 1 March 2026

Merck stock heads into Monday with Keytruda, Welireg cancer data and FDA review dates on deck

Merck stock heads into Monday with Keytruda, Welireg cancer data and FDA review dates on deck

Merck shares rose 3.8% to $123.82 Friday, trading on heavy volume. The company reported Phase 3 trial results showing Keytruda-based combinations improved survival in ovarian and kidney cancers. The FDA set June 19 and Oct. 4, 2026, target dates for reviews of Keytruda and Welireg combinations in kidney cancer. Keytruda accounted for nearly half of Merck’s 2025 revenue, with major patents expiring in 2028.
1 March 2026
·

Stock Market Today

  • Ford Launches Ford Pro AI and V2H Pilot to Expand Digital and Energy Revenue Streams
    March 21, 2026, 11:28 PM EDT. Ford Motor (NYSE:F) introduced Ford Pro AI, a connected fleet management software targeting commercial customers, and launched a vehicle-to-home (V2H) energy pilot with Puget Sound Energy and ChargeScape. Using EVs like the F-150 Lightning, the V2H project tests supplying backup power to homes, highlighting Ford's push into software and energy services. These initiatives aim to create recurring revenue beyond traditional manufacturing, aligning with trends among automakers such as GM, Stellantis, and Tesla. Ford Pro AI helps commercial fleets optimize operations by analyzing vehicle data to reduce downtime. The company's stock trades at $11.52, with a 21.1% one-year and 24.8% five-year return, reflecting investor confidence in its strategic shift toward connected technologies and grid integration. However, execution risks remain as Ford invests heavily in these areas amid industry competition and regulatory pressures.
Go toTop